CLEVELAND CLINIC HOSPITAL
- Type
- Teaching hospital
- Where
- CLEVELAND, OH
- Medicare CCN
- 360180
- Received
- $48,983,037 in 4,159 records, 2019 ($10,490,160 general, $38,492,876 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 963 | $10,490,160 |
| 2019 | Research payment | 3,196 | $38,492,876 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 3,196 | $38,492,876 |
| Royalty or License | 93 | $5,073,353 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 104 | $1,888,988 |
| Grant | 99 | $1,178,662 |
| Consulting Fee | 32 | $792,802 |
| Space rental or facility fees (teaching hospital only) | 200 | $691,831 |
| Education | 41 | $425,620 |
| Charitable Contribution | 10 | $262,439 |
| Gift | 366 | $159,759 |
| Honoraria | 1 | $8,500 |
| Travel and Lodging | 8 | $5,839 |
| Food and Beverage | 9 | $2,364 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $194,123 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $147,125 | Research payment | Cash or cash equivalent | Artis zee Device, AT - Fixed interventional x-ray/angiography fluoroscopy | Cardiac Clinical AT Fusion | 2019 |
| 2019-12-31 | Intuitive Surgical, Inc. | $96,800 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | Carl Zeiss Meditec, Inc. | $42,932 | Consulting Fee | In-kind items and services | OPMI Lumera Device, Surgical Microscope | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $37,853 | Research payment | In-kind items and services | An Open Label, Randomised, Multi Drug, Biomarker Directed, Multi Centre, Multi arm Phase 1b Study in patients with Muscl | 2019 | |
| 2019-12-31 | KARL STORZ Endoscopy-America | $22,909 | Research payment | In-kind items and services | ICG System Device, LAPAROSCOPY | Efficacy of Near Infrared Incisionless Fluorescent Cholangiography (NIFC) During Laparoscopic Cholec | 2019 |
| 2019-12-31 | Philips North America LLC | $20,854 | Research payment | Cash or cash equivalent | Ingenia 3 0T R5 Device, Devices | 2019 | |
| 2019-12-31 | Philips North America LLC | $16,854 | Research payment | Cash or cash equivalent | Ingenia 3 0T R5 Device, Devices | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $15,805 | Research payment | Cash or cash equivalent | SC2000 Device, US - Ultrasound Systems | Structural Heart Disease Quantification Clinical Feedback | 2019 |
| 2019-12-31 | AngioDynamics, Inc. | $11,302 | Education | In-kind items and services | Solero Device, Oncology Surgery | 2019 | |
| 2019-12-31 | Merck Sharp & Dohme LLC | $10,200 | Research payment | Cash or cash equivalent | JANUVIA Drug, ENDOCRINOLOGY | CC Clinical Inertia part II | 2019 |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $5,214 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Merck Sharp & Dohme LLC | $5,121 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2019 |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $5,081 | Research payment | Cash or cash equivalent | S3000 HELX Device, US - Ultrasound Systems | Ultrasonic Mapping of Carotid Plaque | 2019 |
| 2019-12-31 | Eisai Inc. | $4,257 | Research payment | Cash or cash equivalent | Drug | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Ef | 2019 |
| 2019-12-31 | Eisai Inc. | $4,257 | Research payment | Cash or cash equivalent | Drug | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Ef | 2019 |
| 2019-12-31 | Eisai Inc. | $4,257 | Research payment | Cash or cash equivalent | Drug | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Ef | 2019 |
| 2019-12-31 | AstraZeneca UK Limited | $3,159 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-12-31 | Eisai Inc. | $2,994 | Research payment | Cash or cash equivalent | Drug | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Ef | 2019 |
| 2019-12-31 | Eisai Inc. | $2,994 | Research payment | Cash or cash equivalent | Drug | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Ef | 2019 |
| 2019-12-31 | Eisai Inc. | $2,994 | Research payment | Cash or cash equivalent | Drug | A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Ef | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1,545 | Research payment | In-kind items and services | An Open Label, Randomised, Multi Drug, Biomarker Directed, Multi Centre, Multi arm Phase 1b Study in patients with Muscl | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $1,393 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Allergan, Inc. | $1,080 | Research payment | Cash or cash equivalent | A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamoreli | 2019 | |
| 2019-12-31 | Medtronic MiniMed, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-31 | FUJIFILM SonoSite, Inc. | $626 | Education | In-kind items and services | iViz Ultrasound System Device, Medical Device | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $575 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati | 2019 |
| 2019-12-31 | Stryker Corporation | $565 | Gift | In-kind items and services | AXS UNIVERSAL Device, ASPIRATION | 2019 | |
| 2019-12-31 | Stryker Corporation | $565 | Gift | In-kind items and services | AXS UNIVERSAL Device, ASPIRATION | 2019 | |
| 2019-12-31 | Masimo Corporation | $525 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-31 | Masimo Corporation | $390 | Education | In-kind items and services | SedLine Device, Devices | 2019 | |
| 2019-12-31 | Masimo Corporation | $366 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $353 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $345 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Masimo Corporation | $128 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $100 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Masimo Corporation | $82 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-31 | Abbott Laboratories | $60 | Research payment | In-kind items and services | Deep Brain Stimulation Device, Cardiac Arrhythmias and Heart Failure | Abbott DBS Registry of Outcomes for Indications Over Time (ADROIT) | 2019 |
| 2019-12-31 | Abbott Laboratories | $60 | Research payment | In-kind items and services | Deep Brain Stimulation Device, Cardiac Arrhythmias and Heart Failure | Abbott DBS Registry of Outcomes for Indications Over Time (ADROIT) | 2019 |
| 2019-12-31 | Masimo Corporation | $52 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-31 | Masimo Corporation | $46 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-31 | Abbott Laboratories | $45 | Research payment | In-kind items and services | TriClip Tricuspid Repair Device Device, Cardiac Arrhythmias and Heart Failure | TRILUMINATE Pivotal Trial | 2019 |
| 2019-12-31 | Abbott Laboratories | $45 | Research payment | In-kind items and services | Deep Brain Stimulation Device, Cardiac Arrhythmias and Heart Failure | Abbott DBS Registry of Outcomes for Indications Over Time (ADROIT) | 2019 |
| 2019-12-31 | Abbott Laboratories | $45 | Research payment | In-kind items and services | Deep Brain Stimulation Device, Cardiac Arrhythmias and Heart Failure | Abbott DBS Registry of Outcomes for Indications Over Time (ADROIT) | 2019 |
| 2019-12-31 | Abbott Laboratories | $40 | Research payment | In-kind items and services | Deep Brain Stimulation Device, Cardiac Arrhythmias and Heart Failure | Abbott DBS Registry of Outcomes for Indications Over Time (ADROIT) | 2019 |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $12 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Medtronic Vascular, Inc. | $10 | Research payment | In-kind items and services | ECG Belt | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $70,443 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk | 2019 | |
| 2019-12-30 | ABBVIE INC. | $8,860 | Research payment | Cash or cash equivalent | M16-415 | 2019 | |
| 2019-12-30 | Ethicon Endo-Surgery Inc. | $1,000 | Research payment | Cash or cash equivalent | NEUWAVE Flex Microwave Ablation System Device, Ablation System | A Multicentered Study of the NEUWAVE Flex Microwave Ablation System in the Ablation of Medically Inoperable Primary Soft | 2019 |
| 2019-12-29 | KARL STORZ Endoscopy-America | $210 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $90 | Gift | In-kind items and services | TELESCOPE, HOPKINS II, 0', 4MM DIAMETER Device, ENT | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $90 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $60 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $60 | Gift | In-kind items and services | LIGHT CABLE, 3.5MM X 300CM. LGTH 9.8 FT Device, VIDEOIMAGING | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $60 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $60 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $60 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | URETERO-RENO-FIBERSCOPE FLEX-X Device, UROLOGY | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE, HOPKINS II, 0', 4MM DIAMETER Device, ENT | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE, HOPKINS II, 0', 4MM DIAMETER Device, ENT | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-12-29 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | IRRIGATION SHEATH, 5.0MM X 14CM, FOR USE Device, NEUROSURGERY | 2019 | |
| 2019-12-27 | Janssen Research & Development, LLC | $12,004 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $210 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $150 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $120 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $90 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $90 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $60 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $60 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $60 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $60 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE, HOPKINS II, 0', 4MM DIAMETER Device, ENT | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE, HOPKINS II, 0', 4MM DIAMETER Device, ENT | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE, HOPKINS II, 0', 4MM DIAMETER Device, ENT | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE,HOPKINS II, 0, ENLARGED VIEW, Device, LAPAROSCOPY | 2019 | |
| 2019-12-27 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | LIGHT CABLE, 3.5MM X 300CM. LGTH 9.8 FT Device, VIDEOIMAGING | 2019 | |
| 2019-12-26 | Abbott Laboratories | $1,750 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MultiPoint Pacing Post Market Study | 2019 |
| 2019-12-26 | Abbott Laboratories | $1,750 | Research payment | Cash or cash equivalent | Durata Leads Device, Cardiac Arrhythmias and Heart Failure | SJM Cardiac Lead Assessment Study | 2019 |
| 2019-12-26 | Covidien LP | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-26 | United Therapeutics Corporation | $1,405 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTIN | 2019 |
| 2019-12-26 | United Therapeutics Corporation | $1,255 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTIN | 2019 |
| 2019-12-26 | United Therapeutics Corporation | $483 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2019 |
| 2019-12-26 | United Therapeutics Corporation | $378 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2019 |
| 2019-12-26 | United Therapeutics Corporation | $250 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2019 |
| 2019-12-26 | United Therapeutics Corporation | $250 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2019 |
| 2019-12-25 | AstraZeneca UK Limited | $20,003 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-12-24 | Amgen Inc. | $3,450 | Research payment | Cash or cash equivalent | Parsabiv Biological, Nephrology | Pediatric Multi-Dose | 2019 |
| 2019-12-23 | Eli Lilly and Company | $33,584 | Research payment | Cash or cash equivalent | A PHASE 2 STUDY OF LY2157299 MONOHYDRATE MONOTHERAPY OR LY2157299 MONOHYDRATE PLUS LOMUSTINE THERAPY COMPARED TO LOMUSTI | 2019 | |
| 2019-12-23 | Janssen Research & Development, LLC | $5,460 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2019 | |
| 2019-12-23 | Novo Nordisk AS | $3,589 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-12-22 | AstraZeneca Pharmaceuticals LP | $1,050 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2019 | |
| 2019-12-21 | CSL Behring | $109,590 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2019 | |
| 2019-12-21 | Novo Nordisk Inc | $42,000 | Research payment | Cash or cash equivalent | Mapping and Consequences of Mild to Moderate Hypoglycemia | 2019 | |
| 2019-12-20 | Genentech, Inc. | $50,162 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TO EVALUATE SAFETY AND EFFICACY OF IDASANUTLIN IN POLYCYTHEMIA VERA PATIENTS | 2019 |
| 2019-12-20 | E.R. Squibb & Sons, L.L.C. | $23,101 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | PH II TRIAL OF INTERMITTENT THERAPY IN PATIENTS WITH METASTIC RENAL CELL CARCINOMA RECEIVING IPILIMUMAB AND OR NIVOLUMAB | 2019 |
| 2019-12-20 | Edwards Lifesciences Corporation | $3,517 | Research payment | Cash or cash equivalent | Commence Study 2012-02 | 2019 | |
| 2019-12-19 | Siemens Medical Solutions USA, Inc. | $501,840 | Royalty or License | Cash or cash equivalent | 2019 | ||
| 2019-12-19 | Novo Nordisk Inc | $80,470 | Research payment | Cash or cash equivalent | PersonalizedObesity&Metabolic Score(POMS)Promote Risk Reduction for Obesity-Related Adverse Outcomes | 2019 | |
| 2019-12-19 | EyePoint Pharmaceuticals US, Inc. | $80,000 | Research payment | Cash or cash equivalent | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | Pending Registration: Prospective Imaging of the Intravitreal Fluocinolone Acetonide Implant Using Fluorescein Angiograp | 2019 |
| 2019-12-19 | Edwards Lifesciences Corporation | $67,600 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2019 | |
| 2019-12-19 | Medical Device Business Services, Inc. | $31,337 | Research payment | Cash or cash equivalent | Evaluation of QDOT MICRO catheter for pulmonary vein isolation in subjects with Paroxysmal Atrial Fibrillation | 2019 | |
| 2019-12-19 | Amneal Pharmaceuticals LLC | $6,465 | Research payment | Cash or cash equivalent | IR CD-LD Drug, NEUROLOGY | A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in | 2019 |
| 2019-12-19 | Janssen Research & Development, LLC | $5,268 | Research payment | Cash or cash equivalent | Association between HSD3B1 Genotype, Tissue Androgens and AR Signaling in Normal and Prostate Cancer Tissue of Men with | 2019 | |
| 2019-12-19 | Abbott Laboratories | $5,000 | Research payment | Cash or cash equivalent | Infinity DBS Device, Cardiac Arrhythmias and Heart Failure | Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool | 2019 |
| 2019-12-19 | B. Braun Medical Inc. | $5,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-19 | Amneal Pharmaceuticals LLC | $4,267 | Research payment | Cash or cash equivalent | IR CD-LD Drug, NEUROLOGY | A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in | 2019 |
| 2019-12-19 | Genentech, Inc. | $3,955 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-12-19 | Janssen Research & Development, LLC | $3,223 | Research payment | Cash or cash equivalent | A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone ( | 2019 | |
| 2019-12-19 | Bolton Medical Inc | $3,000 | Research payment | Cash or cash equivalent | Device | RelayPro-A IP-0015-16 | 2019 |
| 2019-12-19 | Janssen Research & Development, LLC | $2,230 | Research payment | Cash or cash equivalent | A Multicenter, Open-Label, Single-arm Phase 2 Study of Abiraterone Acetate Plus Prednisone in subjects with Advanced Pro | 2019 | |
| 2019-12-19 | Incyte Corporation | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2019 | |
| 2019-12-19 | Genentech, Inc. | $1,438 | Research payment | Cash or cash equivalent | Drug | VA2 PHIII YOSEMITE | 2019 |
| 2019-12-19 | Genentech, Inc. | $1,437 | Research payment | Cash or cash equivalent | Drug | VA2 PHIII RHINE | 2019 |
| 2019-12-19 | Genentech, Inc. | $1,300 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2019 |
| 2019-12-19 | Genentech, Inc. | $1,300 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2019 |
| 2019-12-19 | Medical Device Business Services, Inc. | $1,291 | Research payment | Cash or cash equivalent | EMBOTRAP II Revascularization Device Device, Neurovascular | EmboTrap Revascularization Device CNV_2017_02 Embotrap extraction & Clot EvaLuation & Lesion Evaluation for NeuroThrombe | 2019 |
| 2019-12-19 | Genentech, Inc. | $1,122 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2019 |
| 2019-12-19 | Genentech, Inc. | $1,122 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2019 |
| 2019-12-19 | Abbott Laboratories | $1,103 | Research payment | Cash or cash equivalent | Trifecta Valve Device, Cardiac Arrhythmias and Heart Failure | Long Term Follow Up of the St. Jude Medical Trifecta Valve | 2019 |
| 2019-12-19 | Abbott Laboratories | $119 | Research payment | Cash or cash equivalent | Trifecta Valve Device, Cardiac Arrhythmias and Heart Failure | Long Term Follow Up of the St. Jude Medical Trifecta Valve | 2019 |
| 2019-12-19 | Meridian Bioscience Inc. | $114 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-12-18 | Amgen Inc. | $25,222 | Research payment | Cash or cash equivalent | Effectively identifying sources of subpopulation heterogeneity from real-world databases as well as optimal designs of m | 2019 | |
| 2019-12-18 | Medtronic Vascular, Inc. | $24,426 | Research payment | Cash or cash equivalent | Arctic Front Device, Ablation | STOP AF First | 2019 |
| 2019-12-18 | Aerie Pharmaceuticals, Inc. | $14,150 | Research payment | Cash or cash equivalent | A Study Assessing AR-13503 Implant Alone and in Combination With Aflibercept in Subjects With nAMD or DME | 2019 | |
| 2019-12-18 | Gilead Sciences, Inc. | $7,930 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Activ | 2019 | |
| 2019-12-18 | Genentech, Inc. | $3,564 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2019 |
| 2019-12-18 | Edwards Lifesciences Corporation | $1,980 | Research payment | Cash or cash equivalent | ASCEND | 2019 | |
| 2019-12-18 | SEAGEN INC. | $1,624 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | A Phase II Study of Single Agent Brentuximab Vedotin in RelapsedRefractory CD30 Low 10 and Negative MatureT Cell Lymphom | 2019 |
| 2019-12-18 | Gilead Sciences, Inc. | $1,576 | Research payment | Cash or cash equivalent | Cayston Drug, RESP | Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg | 2019 |
| 2019-12-18 | Medical Device Business Services, Inc. | $1,320 | Research payment | Cash or cash equivalent | Thermocool Device, Therapeutic Catheters | Prospective Review of the Safety and Effectiveness of the THERMOCOOL SMARTTOUCH SF Catheter Evaluated for Treating Sympt | 2019 |
| 2019-12-18 | Edwards Lifesciences Corporation | $1,300 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Safety and Effectiveness of Edwards Lifesciences SAPIEN3 Transcatheter Heart Valve THV in the Chinese Population | 2019 |
| 2019-12-17 | Teva Pharmaceuticals USA, Inc. | $302,883 | Research payment | Cash or cash equivalent | Ajovy Drug, Central Nervous System | Clinical characteristics, healthcare utilization and outcomes of patients with migraine | 2019 |
| 2019-12-17 | Allergan, Inc. | $86,404 | Research payment | Cash or cash equivalent | OZURDEX Drug, RETINA | Prospective Randomized Comparative Trial for Combination Dexamethasone Implant with PRN Anti-VEGF therapy to Anti-VEGF T | 2019 |
| 2019-12-17 | Neurocrine BioSciences, Inc. | $18,680 | Research payment | Cash or cash equivalent | A RANDOMIZED, PLACEBO SURGERY CONTROLLED, DOUBLE-BLINDED, MULTI-CENTER, PHASE 2 CLINICAL TRIAL, EVALUATING THE EFFICACY | 2019 | |
| 2019-12-17 | Medical Device Business Services, Inc. | $8,929 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-17 | Genentech, Inc. | $6,368 | Research payment | Cash or cash equivalent | Drug | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2019 |
| 2019-12-17 | BioFire Diagnostics, LLC | $4,849 | Research payment | Cash or cash equivalent | BioFire FilmArray 2.0 (FLM2-ASY-0001R) Device, Clinical Diagnostics | Respiratory Tract Infections: Early Detection, Early Treatment | 2019 |
| 2019-12-17 | BioFire Diagnostics, LLC | $3,029 | Research payment | Cash or cash equivalent | BioFire FilmArray RP2 30 Pouch Kit (RFIT-ASY-0129) Device, Clinical Diagnostics | Respiratory Tract Infections: Early Detection, Early Treatment | 2019 |
| 2019-12-17 | Zimmer Biomet Holdings, Inc. | $2,745 | Education | Cash or cash equivalent | Comprehensive Anatomic Device, Extremities | 2019 | |
| 2019-12-17 | Neurocrine BioSciences, Inc. | $2,700 | Research payment | Cash or cash equivalent | A RANDOMIZED, PLACEBO SURGERY CONTROLLED, DOUBLE-BLINDED, MULTI-CENTER, PHASE 2 CLINICAL TRIAL, EVALUATING THE EFFICACY | 2019 | |
| 2019-12-17 | Medtronic, Inc. | $2,250 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2019 |
| 2019-12-17 | Neurocrine BioSciences, Inc. | $1,350 | Research payment | Cash or cash equivalent | A RANDOMIZED, PLACEBO SURGERY CONTROLLED, DOUBLE-BLINDED, MULTI-CENTER, PHASE 2 CLINICAL TRIAL, EVALUATING THE EFFICACY | 2019 | |
| 2019-12-17 | Neurocrine BioSciences, Inc. | $560 | Research payment | Cash or cash equivalent | A RANDOMIZED, PLACEBO SURGERY CONTROLLED, DOUBLE-BLINDED, MULTI-CENTER, PHASE 2 CLINICAL TRIAL, EVALUATING THE EFFICACY | 2019 | |
| 2019-12-17 | Zimmer Biomet Holdings, Inc. | $57 | Food and Beverage | In-kind items and services | The Tether Device, Spine | 2019 | |
| 2019-12-16 | Boston Scientific Corporation | $8,871 | Research payment | Cash or cash equivalent | SPECTRA WAVEWRITER Device, PAIN MANAGEMENT | COMBO | 2019 |
| 2019-12-16 | Gilead Sciences, Inc. | $8,073 | Research payment | Cash or cash equivalent | Phase 1/2 Study of GS-9973 and Chemotherapy in Patients with Acute Lymphoblastic Leukemia (ALL) | 2019 | |
| 2019-12-16 | Clovis Oncology, Inc. | $5,470 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2019 |
| 2019-12-16 | Edwards Lifesciences Corporation | $4,786 | Research payment | Cash or cash equivalent | Early-TAVR Trial 2016-07 | 2019 | |
| 2019-12-16 | Boehringer Ingelheim International GmbH | $3,590 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | EMPA-KIDNEY | 2019 |
| 2019-12-16 | Medtronic Vascular, Inc. | $1,000 | Research payment | Cash or cash equivalent | PERIGON | 2019 | |
| 2019-12-16 | Boston Scientific Corporation | $585 | Research payment | Cash or cash equivalent | SQRX PULSE GENERATOR Device, TACHY | S ICD PAS | 2019 |
| 2019-12-16 | Boston Scientific Corporation | $533 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SAVAL PIVOTAL | 2019 |
| 2019-12-16 | Boston Scientific Corporation | $407 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-12-13 | Edwards Lifesciences Corporation | $23,034 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2019 | |
| 2019-12-13 | Medical Device Business Services, Inc. | $21,264 | Research payment | Cash or cash equivalent | Evaluation of QDOT MICRO catheter for pulmonary vein isolation in subjects with Paroxysmal Atrial Fibrillation | 2019 | |
| 2019-12-13 | Medtronic Vascular, Inc. | $300 | Research payment | Cash or cash equivalent | Viva Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2019 |
| 2019-12-13 | Medtronic Vascular, Inc. | $147 | Research payment | Cash or cash equivalent | PERIGON | 2019 | |
| 2019-12-12 | Regeneron Pharmaceuticals, Inc. | $225,806 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | Advanced Image Analysis | 2019 |
| 2019-12-12 | Regeneron Pharmaceuticals, Inc. | $42,040 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | Evaluation of Imaging Biomarkers with Cytokine Profiling in Diabetic Macular Edema and Retinal Venous Occlusive Disease | 2019 |
| 2019-12-12 | Stryker Corporation | $23,008 | Research payment | Cash or cash equivalent | JOINTCOACH Device, PERFORMANCE SOLUTIONS | PATIENT SATISFACTION AND CLINICAL OUTCOMES USING JOINT TO MANAGE THE EPISODE OF CARE FOR THA AND TKA BUNDLES | 2019 |
| 2019-12-12 | PFIZER INC. | $11,000 | Research payment | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-12-12 | Stryker Corporation | $10,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MAKO Device, KNEES, HIPS | 2019 | |
| 2019-12-12 | Cook Research Incorporated | $5,250 | Research payment | Cash or cash equivalent | Cook Medical Self-Expanding Stent Device, Peripheral Intervention | Zilver PTX V Post Market Study in the US | 2019 |
| 2019-12-12 | Abbott Laboratories | $5,000 | Research payment | Cash or cash equivalent | HeartMate 3 LVAS Device, Cardiac Arrhythmias and Heart Failure | Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3 Continued Access Protocol | 2019 |
| 2019-12-12 | Zimmer Biomet Holdings, Inc. | $3,482 | Education | Cash or cash equivalent | Comprehensive Anatomic Device, Extremities | 2019 | |
| 2019-12-12 | Abbott Laboratories | $2,600 | Research payment | Cash or cash equivalent | SynacAV Device, Cardiac Arrhythmias and Heart Failure | SyncAV Post-Market Trial (SyncAV) | 2019 |
| 2019-12-12 | Allergan, Inc. | $2,202 | Research payment | Cash or cash equivalent | FETZIMA Drug, NEUROSCIENCE | A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT | 2019 |
| 2019-12-12 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | HeartMate 3 LVAS Device, Cardiac Arrhythmias and Heart Failure | Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3 Continued Access Protocol | 2019 |
| 2019-12-12 | Rigel Pharmaceuticals, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-12 | Abbott Laboratories | $1,899 | Research payment | Cash or cash equivalent | Trifecta Valve Device, Cardiac Arrhythmias and Heart Failure | Long Term Follow Up of the St. Jude Medical Trifecta Valve | 2019 |
| 2019-12-12 | Abbott Laboratories | $1,250 | Research payment | Cash or cash equivalent | SynacAV Device, Cardiac Arrhythmias and Heart Failure | SyncAV Post-Market Trial (SyncAV) | 2019 |
| 2019-12-12 | Orthofix Medical, Inc. | $663 | Research payment | Cash or cash equivalent | Spinal-Stim Osteogenesis Stimulator Device, STIMULATOR, BONE GROWTH, NON-INVASIVE | 2019 | |
| 2019-12-12 | Abbott Laboratories | $600 | Research payment | Cash or cash equivalent | Nanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart Failure | A safety and effectiveness trial for a leadless pacemaker system | 2019 |
| 2019-12-12 | Genentech, Inc. | $424 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | ATEZOLIZUMAB IN MUSCLE INVASIVE BLADDER CANCER MIBC | 2019 |
| 2019-12-12 | PFIZER INC. | $234 | Research payment | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2019 |
| 2019-12-11 | Medtronic, Inc. | $62,959 | Research payment | Cash or cash equivalent | Attain Device, Leads | PSR-CVG | 2019 |
| 2019-12-11 | Ortho-Clinical Diagnostics, Inc. | $26,436 | Research payment | Cash or cash equivalent | Clinical Chemistry Device, Diagnostics | hs Troponin I | 2019 |
| 2019-12-11 | KCI USA, Inc. | $25,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PREVENA Device, NON-COVERED | 2019 | |
| 2019-12-11 | KCI USA, Inc. | $25,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PREVENA Device, NON-COVERED | 2019 | |
| 2019-12-11 | Janssen Research & Development, LLC | $7,027 | Research payment | Cash or cash equivalent | A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subject | 2019 | |
| 2019-12-11 | United Therapeutics Corporation | $6,727 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2019 |
| 2019-12-11 | ABBVIE INC. | $6,111 | Research payment | Cash or cash equivalent | M16-415 | 2019 | |
| 2019-12-11 | Corcept Therapeutics | $5,850 | Research payment | Cash or cash equivalent | CORT125134-455 | 2019 | |
| 2019-12-11 | Corcept Therapeutics | $5,850 | Research payment | Cash or cash equivalent | CORT125134-455 | 2019 | |
| 2019-12-11 | Corcept Therapeutics | $4,100 | Research payment | Cash or cash equivalent | CORT125134-455 | 2019 | |
| 2019-12-11 | Corcept Therapeutics | $2,275 | Research payment | Cash or cash equivalent | CORT125134-455 | 2019 | |
| 2019-12-11 | United Therapeutics Corporation | $1,989 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2019 |
| 2019-12-11 | Merck Sharp & Dohme LLC | $656 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemo | 2019 |
| 2019-12-11 | Medtronic USA, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | INTERSTIM Device, Sacral Nerve Stimulation | 2019 | |
| 2019-12-11 | United Therapeutics Corporation | $241 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2019 |
| 2019-12-10 | Edwards Lifesciences Corporation | $35,368 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER II 2010-12 | 2019 |
| 2019-12-10 | Edwards Lifesciences Corporation | $32,000 | Research payment | Cash or cash equivalent | ASCEND | 2019 | |
| 2019-12-10 | Edwards Lifesciences Corporation | $13,175 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER II 2010-12 | 2019 |
| 2019-12-10 | PFIZER INC. | $13,020 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 | 2019 | |
| 2019-12-10 | Edwards Lifesciences Corporation | $9,050 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial 2018-19 | 2019 | |
| 2019-12-10 | Allergan, Inc. | $7,145 | Research payment | Cash or cash equivalent | FETZIMA Drug, NEUROSCIENCE | A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT | 2019 |
The latest 200 records of 4,159.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Cleveland, OH, county Cuyahoga County, OH, state Ohio; placed by its city name.
| Measure | Place (city or town) Cleveland, OH | County Cuyahoga County, OH | State Ohio |
|---|---|---|---|
| Population B01003 | 366,097 | 1,245,873 | 11,810,293 |
| Population, 2020 census P1 | 372,624 | 1,264,817 | 11,799,448 |
| Median age B01002 | 36.3 | 40.4 | 39.7 |
| Under 18 B01001 | 21.0% | 20.5% | 22.0% |
| 65 and over B01001 | 15.2% | 19.5% | 18.3% |
| Households B11001 | 169,683 | 554,551 | 4,863,191 |
| Foreign born B05002 | 6.3% | 7.7% | 5.2% |
| Median household income B19013 | $40,801 | $64,468 | $71,389 |
| Median family income B19113 | $50,461 | $89,252 | $92,749 |
| Per capita income B19301 | $28,266 | $42,747 | $40,552 |
| Poverty rate B17001 | 30.6% | 16.1% | 13.3% |
| Unemployment rate B23025 | 10.8% | 6.6% | 4.8% |
| Civilian labor force B23025 | 180,027 | 650,577 | 5,994,779 |
| Mean commute (minutes) B08013 | 22.5 | 23.3 | 23.4 |
| Bachelor's degree or higher B15003 | 22.4% | 36.5% | 31.5% |
| Housing units B25001 | 201,141 | 615,331 | 5,292,391 |
| Owner-occupied B25003 | 41.7% | 59.4% | 67.2% |
| Renters B25003 | 58.3% | 40.6% | 32.8% |
| Median home value B25077 | $102,000 | $195,400 | $214,800 |
| Median gross rent B25064 | $945 | $1,060 | $1,034 |
| White, not Hispanic B03002 | 33.7% | 56.5% | 75.8% |
| Black B03002 | 45.1% | 28.5% | 12.0% |
| Hispanic or Latino B03002 | 13.2% | 7.0% | 4.8% |
| Asian B03002 | 2.6% | 3.3% | 2.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Cleveland, OH.
Comments